Edaravone May Prevent Ferroptosis in ALS.
2020
Аутори:
Spasić, SnežanaNikolić-Kokić, Aleksandra
Miletić, Srđan
Oreščanin Dušić, Zorana
Spasić, Mihajlo
Blagojević, Duško
Stević, Zorica
Тип документа:
Чланак у часопису (Објављена верзија)
,
© Bentham Science Publishers
Метаподаци
Приказ свих података о документуАпстракт:
Radicava™ (Edaravone) was approved the Food and Drug Administration (FDA) as a new treatment for amyotrophic lateral sclerosis (ALS). Edaravone is a synthetic antioxidant that specifically targets oxidative damage interacting with lipid radicals in the cell. In ALS disease the multiple cell types are involved in devastating loss of motor neurons. Mutations and biochemical changes in various cell types jointly contribute to motor neuron death, disease onset, and disease progression. The overall mechanism of neurodegeneration in ALS is still not completely understood. Dying motor neurons have been reported to exhibit features of apoptosis. However, non-apoptotic features of dying motor neurons have also been reported such as ferroptosis. The role of Edaravone in the prevention of ferroptosis in parallel with other therapeutic approaches to ALS therapy is discussed.
Кључне речи:
Edaravone; Amyotrophic lateral sclerosis (ALS); Ferroptosis; Neurodegeneration; Neurons; TherapyИзвор:
Current Drug Targets, 2020, 21, 8, 776-780
DOI: 10.2174/1389450121666200220123305
ISSN: 1873-5592
PubMed: 32077821
WoS: 000542986600002
Scopus: 2-s2.0-85087096289
URI
https://www.eurekaselect.com/179582/articlehttp://www.ncbi.nlm.nih.gov/pubmed/32077821
https://radar.ibiss.bg.ac.rs/handle/123456789/3757